CoChat

CDK4/6 Inhibitors Sensitize Rb-positive Sarcoma Cells to Wee1 Kinase Inhibition through Reversible Cell-Cycle Arrest

Open access

Published version of a preprint

The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.

Abstract

Abstract Research into the biology of soft tissue sarcomas has uncovered very few effective treatment strategies that improve upon the current standard of care which usually involves surgery, radiation, and chemotherapy. Many patients with large (>5 cm), high-grade sarcomas develop recurrence, and at that point have limited treatment options available. One challenge is the heterogeneity of genetic drivers of sarcomas, and many of these are not validated targets. Even when such genes are tractable targets, the rarity of each subtype of sarcoma makes advances in research slow. Here we describe the development of a synergistic combination treatment strategy that may be applicable in both soft tissue sarcomas as well as sarcomas of bone that takes advantage of targeting the cell cycle. We show that Rb-positive cell lines treated with the CDK4/6 inhibitor palbociclib reversibly arrest in the G1 phase of the cell cycle, and upon drug removal cells progress through the cell cycle as expected within 6–24 hours. Using a long-term high-throughput assay that allows us to examine drugs in different sequences or concurrently, we found that palbociclib-induced cell-cycle arrest poises Rb-positive sarcoma cells (SK-LMS1 and HT-1080) to be more sensitive to agents that work preferentially in S–G2 phase such as doxorubicin and Wee1 kinase inhibitors (AZD1775). The synergy between palbociclib and AZD1775 was also validated in vivo using SK-LMS1 xenografts as well as Rb-positive patient-derived xenografts (PDX) developed from leiomyosarcoma patients. This work provides the necessary preclinical data in support of a clinical trial utilizing this treatment strategy. Mol Cancer Ther; 16(9); 1751–64. ©2017 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1535-7163.mct-17-0040

Cites

51 of 51 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 51 references

Cited by

See all 55

Metadata

Authors
Francis, A. M., Alexander, A., Liu, Y., Vijayaraghavan, S., Low, K. H., Yang, D., Bui, T., Somaiah, N., Ravi, V., Keyomarsi, K., & Hunt, K. K.
Affiliations
The University of Texas MD Anderson Cancer Center (US)
Venue
Molecular Cancer Therapeutics
Published
2017-09-01
Volume
16
Issue
9
Pages
1751-1764
ISSN
  • 1535-7163 (ISSN-L)
  • 1538-8514
OpenAlex
W2624850365
Cited by
54
References
51
Citations by year
2026: 6 · 2025: 1 · 2024: 6 · 2023: 8 · 2022: 7 · 2021: 6 · 2020: 5 · 2019: 6 · 2018: 7 · 2017: 2
FWCI
4.52
Type
journal article
Language
en
Open access
Locations
  • Molecular Cancer Therapeutics (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • National Institutes of Health (5r01ca087548-14)
  • National Cancer Institute (R01-CA087548, R01CA223772, R01CA152228, T32CA009599, P30CA016672)
Topics
  • Health Sciences › Medicine › Oncology › Sarcoma Diagnosis and Treatment
  • Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
  • Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
Keywords
CDK4/6 inhibitors, palbociclib, Wee1 kinase inhibitor, AZD1775, soft tissue sarcoma, bone sarcoma, leiomyosarcoma, G1 cell cycle arrest, drug synergy, combination therapy, patient-derived xenografts, doxorubicin
MeSH terms
Animals, Disease Models, Animal, Humans, Male, Nuclear Proteins, Piperazines, Protein-Tyrosine Kinases, Pyrazoles, Pyridines, Pyrimidines, Pyrimidinones, Sarcoma, Retinoblastoma Protein, Cell Cycle Proteins, Drug Resistance, Neoplasm, Xenograft Model Antitumor Assays, Cell Line, Tumor, Protein Kinase Inhibitors, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6, Mice, Gene Knockdown Techniques, Cell Cycle Checkpoints

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: CDK4/6 Inhibitors Sensitize Rb-positive Sarcoma Cells to Wee1 Kinase Inhibition through Reversible Cell-Cycle Arrest. https://app.cochat.ai/papers/10.1158/1535-7163.mct-17-0040
The paper
Francis, A. M., Alexander, A., Liu, Y., Vijayaraghavan, S., Low, K. H., Yang, D., Bui, T., Somaiah, N., Ravi, V., Keyomarsi, K., & Hunt, K. K. (2017). CDK4/6 Inhibitors Sensitize Rb-positive Sarcoma Cells to Wee1 Kinase Inhibition through Reversible Cell-Cycle Arrest. Molecular Cancer Therapeutics. https://doi.org/10.1158/1535-7163.mct-17-0040

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.